Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 90,600 shares, a growth of 19.2% from the February 13th total of 76,000 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 102,400 shares, the short-interest ratio is currently 0.9 days.

Analysts Set New Price Targets

AVTX has been the subject of a number of research analyst reports. BTIG Research initiated coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target for the company. Piper Sandler assumed coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. Finally, Wedbush assumed coverage on Avalo Therapeutics in a report on Friday, February 21st. They issued an “outperform” rating and a $18.00 target price for the company. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $35.33.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Velan Capital Investment Management LP bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $817,000. BVF Inc. IL grew its position in shares of Avalo Therapeutics by 7.2% in the 4th quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock valued at $7,703,000 after buying an additional 69,679 shares during the last quarter. Allostery Investments LP bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $545,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $168,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Stock Up 2.8 %

Shares of AVTX opened at $7.99 on Thursday. Avalo Therapeutics has a 12-month low of $4.36 and a 12-month high of $34.46. The business has a 50-day simple moving average of $7.42 and a two-hundred day simple moving average of $9.11.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.